Switch theme
Sign up to access all valuation multiples
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
1978
3.7K+
LTM Revenue $1.8B
LTM EBITDA $381M
$6.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biocon has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of $381M.
In the most recent fiscal year, Biocon achieved revenue of $1.8B and an EBITDA of $524M.
Biocon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biocon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $381M | XXX | $524M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $193M | XXX | $156M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $119M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biocon's stock price is INR 336 (or $4).
Biocon has current market cap of INR 402B (or $4.7B), and EV of INR 535B (or $6.3B).
See Biocon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.3B | $4.7B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biocon has market cap of $4.7B and EV of $6.3B.
Biocon's trades at 3.6x EV/Revenue multiple, and 12.3x EV/EBITDA.
Equity research analysts estimate Biocon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biocon has a P/E ratio of 42.5x.
See valuation multiples for Biocon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.7B | XXX | $4.7B | XXX | XXX | XXX |
| EV (current) | $6.3B | XXX | $6.3B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 16.4x | XXX | 12.3x | XXX | XXX | XXX |
| EV/EBIT | 32.6x | XXX | 40.1x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 42.5x | XXX | 39.6x | XXX | XXX | XXX |
| EV/FCF | 152.8x | XXX | 34.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiocon's last 12 month revenue growth is 16%
Biocon's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Biocon's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biocon's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biocon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | 45% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biocon acquired XXX companies to date.
Last acquisition by Biocon was XXXXXXXX, XXXXX XXXXX XXXXXX . Biocon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biocon founded? | Biocon was founded in 1978. |
| Where is Biocon headquartered? | Biocon is headquartered in India. |
| How many employees does Biocon have? | As of today, Biocon has 3.7K+ employees. |
| Who is the CEO of Biocon? | Biocon's CEO is Mr. Siddharth Mittal. |
| Is Biocon publicy listed? | Yes, Biocon is a public company listed on BOM. |
| What is the stock symbol of Biocon? | Biocon trades under 532523 ticker. |
| When did Biocon go public? | Biocon went public in 2004. |
| Who are competitors of Biocon? | Similar companies to Biocon include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biocon? | Biocon's current market cap is $4.7B |
| What is the current revenue of Biocon? | Biocon's last 12 months revenue is $1.8B. |
| What is the current revenue growth of Biocon? | Biocon revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Biocon? | Current revenue multiple of Biocon is 3.4x. |
| Is Biocon profitable? | Yes, Biocon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biocon? | Biocon's last 12 months EBITDA is $381M. |
| What is Biocon's EBITDA margin? | Biocon's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Biocon? | Current EBITDA multiple of Biocon is 16.4x. |
| What is the current FCF of Biocon? | Biocon's last 12 months FCF is $41.0M. |
| What is Biocon's FCF margin? | Biocon's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Biocon? | Current FCF multiple of Biocon is 152.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
